CD19 and diffuse large B-cell lymphoma: For example, ET019003 cells are novel anti-CD19 gamma/delta TCR T-cells that were evaluated in r/r DLBCL with a reported ORR of 87.5%, CRR of 75%, and 3-year OS of 75%.